Curis (CRIS)
(Delayed Data from NSDQ)
$8.13 USD
-0.37 (-4.35%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $8.03 -0.10 (-1.23%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
Curis, Inc. [CRIS]
Reports for Purchase
Showing records 21 - 40 ( 304 total )
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Data For Emavusertib in Lymphoma to be Presented at EHA
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Clinical Holds in Effect; Data Update at ASCO for Emavusertib in Lymphoma
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
FDA Places Partial Clinical Hold on TakeAim Lymphoma Study of Emavusertib
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Partial Clinical Hold Placed on TakeAim Leukemia Study of Emavusertib (CA-4948)
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Results; Multiple Data Readouts Expected in 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Positive Updates for Both CA-4948 and CI-8993 Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results; Important Data for CA-4948 in AML and MDS and CI-8993 Safety Data Expected in January
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Combination Therapy Initiated in R/R Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Results; Several Key Milestones Anticipated in 2H21
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
More Positive Data From the Phase 1/2 Study of CA-4948 in AML and MDS at EHA 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Results; EHA Abstract Highlights Impressive Data for CA-4948 in AML and MDS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
CA-4948 Receives Orphan Drug Designation for the Treatment of AML and MDS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
4Q20 Results; Additional CA-4948 Data in AML and High-Risk MDS Patients Expected Mid-2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in Phase 1 Combination Study of CA-4948 With Imbruvica
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Initiation of Phase 2 LUCAS Trial of CA-4948 in MDS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Looking to Several Potential Catalysts in 2021; Raise PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Positive Data for CA-4948 in AML/MDS; Raising PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E